by Sanger sequencing is a technique used for DNA sequencing based on the chain-termination method. It is a cost-effective method for DNA sequencing of genes, genomes, and for linking genomic variants to phenotypes. Sanger sequencing helps in characterization of genomic rearrangements, discovery of SNPs, identification of unknown pathogens, among other applications. Advancements in automation solutions, lab robotics and integration of bioinformatics tools with Sanger sequencing platforms have enhanced throughput and reduced turnaround times for sequencing projects.
The global Sanger sequencing market is estimated to be valued at US$ 10,130.6 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the Global Sanger Sequencing Market are Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ, GenHunter Corporation, GenScript, LGC Biosearch Technologies, Nucleics, Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation.
Some of the key opportunities in the market include increased sequencing applications in microbial genome analysis, metagenomics and infectious disease research.Growing research activities in cancer genomics also present significant market opportunities.
Technological advancements such as automation of library preparation, capillary electrophoresis, and integration of bioinformatics tools with sequencers have enhanced throughput and reduced turnaround times.
Market Drivers
Declining cost of sequencing: Continuous reduction in the cost of sequencing over the years has increased Sanger sequencing applications such as polymorphism detection, MLPA analysis, genetic disease research and gene expression studies.
Rising R&D investments: Increasing investments by pharmaceutical companies, academic institutes and biotech firms in genomics and sequencing technologies is a major factor fueling demand.
Growing importance of genomics in precision medicine: Application of genomic information to guide medical decisions and care customized to individual patient characteristics and conditions is driving incorporation of sequencing in clinical settings.
Current Challenges in Global Sanger Sequencing Market
The global Sanger sequencing market is facing several challenges currently. One of the major challenges is high cost associated with Sanger sequencing. This traditional sequencing method is expensive for large-scale sequencing projects involving whole genome sequencing. It has relatively low throughput and can sequence only 700-900 base pairs in one sequencing run. This limits its use for applications requiring high-throughput sequencing of long genomes. Accuracy is another challenge as occasional errors are introduced during the sequencing process. Furthermore, data analysis and storage of huge sequence data generated through Sanger sequencing poses significant computational challenges. Advances in sequencing technologies have led to the development of next-generation sequencing which is more affordable and scalable for large genome and population sequencing projects. This is a major challenge for the traditional Sanger sequencing market.
SWOT Analysis
Strength: Provides accurate, reliable nucleotide sequence information; Considered the gold standard for validation of other sequencing methods
Weakness: Low throughput limits scale for large sequencing projects; High costs involved for capitals and consumables
Opportunity: Still used for some sequencing applications that require long reads and accuracy; Demand from clinical diagnostics and genetic testing market
Threats: Being replaced by high-throughput next-generation sequencing technologies for most applications; Increased competition from NGS competitors
Geographical Regions of Concentration
In terms of value, the global Sanger sequencing market is highly concentrated in North America currently. This is mainly due to extensive research in genomics and presence of major market players in the US. Advances in precision medicine and growing clinical diagnostics market in the region is also driving the demand. Europe is another leading regional market supported by funding for genomics research and local presence of several sequencing platform vendors. Asia Pacific is poised to be the fastest growing geographical market during the forecast period driven by increasing R&D investments, clinical and industrial applications of sequencing in countries like China, India and Japan. Emerging economies are opening up opportunities despite budget constraints currently.
Fastest Growing Geographical Region
The Asia Pacific region is expected to be the fastest growing geographical market for Sanger sequencing during the forecast period from 2024 to 2031. This growth can be attributed to the improving healthcare infrastructure, rising clinical testing demand and expansion of genomics research in the region’s key economies. In particular, China and India are anticipated to significantly contribute to the market growth in Asia Pacific. Growing initiatives for sequencing genome populations and adoption of sequencing technologies would support market expansion in the region. In addition, presence of less stringent regulations compared to developed markets, lower material and labor costs provide local vendors a favorable platform for business. However, the market still faces certain challenges pertaining to lack of skilled professionals and funding limitations which can restrain the growth to some extent.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research.
2. We have leveraged AI tools to mine information and compile it.
